Abstract
Background: Hyperbaric oxygen (HBO 2 ) therapy has been proposed to treat hypoxaemia and reduce inflammation in COVID-19. Our objective was to analyse safety and efficacy of HBO 2 in treatment of hypoxaemia in patients with COVID-19 and evaluate time to hypoxaemia correction.
Methods: This was a multicentre, open-label randomised controlled trial conducted in Buenos Aires, Argentina, between July and November 2020. Patients with COVID-19 and severe hypoxaemia (SpO 2 ≤90% despite oxygen supplementation) were assigned to receive either HBO 2 treatment or the standard treatment for respiratory symptoms for 7 days. HBO 2 treatment was planned for ≥5 sessions (1 /day) for 90 min at 1.45 atmosphere absolute (ATA). Outcomes were time to normalise oxygen requirement to SpO 2 ≥93%, need for mechanical respiratory assistance, development of acute respiratory distress syndrome and mortality within 30 days. A sample size of 80 patients was estimated, with a planned interim analysis after determining outcomes on 50% of patients.
Results: The trial was stopped after the interim analysis. 40 patients were randomised, 20 in each group, age was 55.2±9.2 years. At admission, frequent symptoms were dyspnoea, fever and odynophagia; SpO 2 was 85.1%±4.3% for the whole group. Patients in the treatment group received an average of 6.2±1.2 HBO 2 sessions. Time to correct hypoxaemia was shorter in treatment group versus control group; median 3 days (IQR 1.0-4.5) versus median 9 days (IQR 5.5-12.5), respectively (p<0.010). OR for recovery from hypoxaemia in the HBO 2 group at day 3 compared with the control group was 23.2 (95% CI 1.6 to 329.6; p=0.001) Treatment had no statistically significant effect on acute respiratory distress syndrome, mechanical ventilation or death within 30 days after admission.
Conclusion: Our findings support the safety and efficacy of HBO 2 in the treatment of COVID-19 and severe hypoxaemia.
Trial registration number: NCT04477954 .
Keywords: COVID-19; hyperbaric medicine; respiratory.
【저자키워드】 COVID-19, respiratory, hyperbaric medicine, 【초록키워드】 Treatment, Inflammation, Efficacy, randomised controlled trial, therapy, Mortality, Trial, Open-label, randomised, mechanical ventilation, Symptom, outcome, Fever, Patient, death, hypoxaemia, age, multicentre, Admission, patients, Dyspnoea, acute respiratory distress, Buenos Aires, hyperbaric oxygen, Support, Sample size, control group, 95% CI, standard treatment, average, syndrome, treatment group, interim analysis, respiratory symptom, treat, oxygen supplementation, Oxygen requirement, time, HBO, evaluate, conducted, median, reduce, assigned, had no, statistically significant, receive, IQR, mechanical respiratory, patients with COVID-19, with COVID-19, 【제목키워드】 Treatment, randomised controlled trial, hyperbaric oxygen, patients with COVID-19,